Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

C4 Therapeutics (CCCC) Tax Provisions (2019 - 2024)

Historic Tax Provisions for C4 Therapeutics (CCCC) over the last 4 years, with Q4 2024 value amounting to $131000.0.

  • C4 Therapeutics' Tax Provisions fell 5270.76% to $131000.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $131000.0, marking a year-over-year decrease of 9426.19%. This contributed to the annual value of $131000.0 for FY2024, which is 8976.56% down from last year.
  • As of Q4 2024, C4 Therapeutics' Tax Provisions stood at $131000.0, which was down 5270.76% from $277000.0 recorded in Q4 2023.
  • Over the past 5 years, C4 Therapeutics' Tax Provisions peaked at $1.0 million during Q3 2023, and registered a low of -$168000.0 during Q2 2020.
  • Its 3-year average for Tax Provisions is $112142.9, with a median of -$124000.0 in 2020.
  • Data for C4 Therapeutics' Tax Provisions shows a peak YoY increase of 2916.67% (in 2020) and a maximum YoY decrease of 12569.23% (in 2020) over the last 5 years.
  • Over the past 3 years, C4 Therapeutics' Tax Provisions (Quarter) stood at -$124000.0 in 2020, then skyrocketed by 323.39% to $277000.0 in 2023, then crashed by 52.71% to $131000.0 in 2024.
  • Its Tax Provisions was $131000.0 in Q4 2024, compared to $277000.0 in Q4 2023 and $1.0 million in Q3 2023.